Oncobax-AK / EverImmune - LARVOL DELTA

Phase 1 results of Oncobax-AK in combination with ipilimumab/nivolumab in advanced clear cell renal cell carcinoma (ccRCC; NCT05865730). (ASCO 2025) - P2 | "This is the first trial targeting patients lacking Akkermansia spp. in their stools. Oncobax-AK, combined with Ipilimuab/Nivolumab in intermediate- and poor-risk IMDC ccRCC, appears safe and may modulate gut microbiota, inflammation, metabolites, and immune profiles."

Combination therapy • IO biomarker • Metastases • P1 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Results of a phase 1 multicenter study on Oncobax®-AK with immunotherapy in renal cell carcinoma (NCT 05865730) (AACR 2025) - P2 | "Only patients who tested negative for stool Akk received 1X oral capsules of Oncobax-AK (a specific strain of SGB9228, p2261) alone for 1 week, followed by a combination with nivolumab plus ipilimumab continuously until progression. This is the first trial targeting patients lacking Akkermansia spp. in their stools. Oncobax®-AK combined with immunotherapy in intermediate- and poor-risk IMDC renal cell carcinoma appears safe and may modulate gut microbiota, inflammation, metabolites, and immune profile, potentially mimicking a responder's profile and leading to clinical and radiological benefits in some patients."

Clinical • IO biomarker • P1 data • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor